

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 5245

D. J. ALLEN, M.D.

A. W. ARLEY, M.D.

J. R. BREWER, M.D.

J. E. ELLIOTT, M.D.

PHONE 255-7831 AREA CODE 406
301 FOURTH AVENUE
HAVRE, MONTANA 59501

A. O. OHLER
BUSINESS MANAGER

G. G. KURTZ, M.D.

C. W. LAWSON, M.D.

D. S. MAC KENZIE, M.D.

J. H. O'LEARY, M.D.

April 4, 1969

Federal Drug Administration
Washington D.C.

Dear Sirs:

I noticed with some consternation that you have received over 3,000 letters opposed to your recent decision about drug combinations, such as Pan Alba. I am writing this letter in order to be put on record that I am heartily in favor of your decision.

I have long felt, as have many of my colleagues, that the combinations are not useful and that the drugs in the combinations are not first or quite often not second choice drugs for the indications that are given by the detail men and the drug ads.

Sincerely,



John R. Brewer, M.D.
Pediatric and Adolescent Medicine

JRB/lv